NEW YORK, March 09, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Obalon Therapeutics, Inc. ("Obalon" or the "Company") (NASDAQ:OBLN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Obalon securities between October 5, 2016 and January 23, 2018, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/obln.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
On January 23, 2018, Obalon announced that it would cancel its previously announced public offering of Obalon common stock after its independent auditor, KPMG LLP, received a complaint from a “purported whistleblower” alleging “improper revenue recognition during the Company's fourth fiscal quarter of 2017.” On this news, Obalon’s share price fell $1.73, or 33.33%, to close at $3.46 on January 23, 2018.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) that the Company recognized revenue in violation of Generally Accepted Accounting principles (“GAAP”); (2) that the Company lacked adequate internal controls over accounting and financial reporting; and (3) that, as a result of the foregoing, the Company’s financial statements and Defendants’ statements about Obalon’s business, operations, and prospects, were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/obln or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Obalon you have until April 16, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



